Over the past 25 years, researchers have worked to understand the complex relationship between FMRP deficiency and the symptoms of FXS and, in the process, have identified several potential targeted therapeutics, some of which have been tested in clinical trials. The gene discussed is FMR1; the disease is hyperinsulinemic hypoglycemia, familial, 4.